VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Texas MPN Workshop 2020 | To JAKi or not to JAKi – treating early MF

Ruben Mesa • 31 Aug 2020
Texas MPN Workshop 2020
Myeloproliferative Neoplasms Fedratinib Ruxolitinib

Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, discusses the issues around early myelofibrosis, and how to treat patients, in particular considering disease burden when selecting a therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Ruben Mesa

2:23
Future therapies for MF: pacritinib, momelotinib, fedratinib & other pathways
Ruben Mesa • 15 Nov 2019
1:15
Ongoing trials of ruxolitinib, momelotinib and imetelstat in myelofibrosis
Ruben Mesa • 2 Dec 2016
1:08
How to manage MPN patients
Ruben Mesa • 18 Apr 2016
1:16
Cytokines and their impact on the severity of myelofibrosis
Ruben Mesa • 22 Jun 2017

Related Videos

2:04
ESH CML/MPNs 2021: what to expect?
Ruben Mesa • 17 Feb 2021
3:22
Transplantation in MF: patient-centered communication and decision making
Ruben Mesa • 17 Feb 2021
4:44
Transplantation in patients with myelofibrosis
Ruben Mesa • 17 Feb 2021
5:11
Haploidentical vs matched donor transplantation in patients with myelofibrosis
Tania Jain • 12 Feb 2021
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals